Karolina Cyll

Karolina Cyll

Auto-generated profile, based on publicly available information

Karolina Cyll

Institute for Cancer Genetics and Informatics, Oslo University Hospital, Oslo, Norway

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 June 2024 in Heliyon
Verified
Journal Article
Open access
WKWanja Kildal
Wanja Kildal
KCKarolina Cyll
Karolina Cyll
JKJoakim Kalsnes
Joakim Kalsnes
RIRakibul Islam
Rakibul Islam
FJFrida M. Julbø
Frida M. Julbø
TSTherese Sørlie
Therese Sørlie
We aimed to develop deep learning (DL) models to detect protein expression in immunohistochemically (IHC) stained tissue-sections, and to compare their accuracy and performance with manually scored clinically relevant proteins in common cancer types.

3 July 2024 in British Journal of Cancer
Verified
Journal Article
Open access
PDF file
KCKarolina Cyll
Karolina Cyll
EHErik Skaaheim Haug
Erik Skaaheim Haug
MPManohar Pradhan
Manohar Pradhan
LVLjiljana Vlatkovic
Ljiljana Vlatkovic
BCBirgitte Carlsen
Birgitte Carlsen
HDHåvard E. Danielsen
Håvard E. Danielsen
Background: Current risk stratification tools for prostate cancer patients under active surveillance (AS) may inadequately identify those needing treatment. We investigated DNA ploidy and PTEN as potential biomarkers to predict aggressive disease in AS patients. Methods: We assessed DNA ploidy by image cytometry and PTEN protein expression by immunohistochemistry in 3197 tumour-containing tissue blocks from 558 patients followed in AS at a Norwegian local hospital. The primary endpoint was treatment, with treatment failure (biochemical recurrence or initiation of salvage therapy) as the secondary endpoint. Results: The combined DNA ploidy and PTEN (DPP) status at diagnosis was associated with treatment-free survival in univariable- and multivariable analysis, with a HR for DPP-aberrant vs. DPP-normal tumours of 2.12 (p < 0.0001) and 1.94 (p < 0.0001), respectively. Integration of DNA ploidy and PTEN status with the Cancer of the Prostate Risk Assessment (CAPRA) score improved risk stratification (c-index difference = 0.025; p = 0.0033). Among the treated patients, those with DPP-aberrant tumours exhibited a significantly higher likelihood of treatment failure (HR 2.01; p = 0.027). Conclusions: DNA ploidy and PTEN could serve as additional biomarkers to identify AS patients at increased risk of developing aggressive disease, enabling earlier intervention for nearly 50% of the patients that will eventually receive treatment with current protocol.